menu
close
Toll-Free 1-866-625-9854

Evipress (Lercanidipine)

Active Ingredient: Lercanidipine
Dosage: 10 mg
Route of Administration: Oral
Dosage Form: Tablets
Quantity per package: 15 pills
Availability: Out of stock

Evipress (Lercanidipine) is intended for hypertension treatment. This preparation relates to the dihydropyridine class of calcium channel blockers. Its main function works by relaxing and opening the blood vessels. It allows the blood to circulate more freely through the body.

Evipress is currently unavailable but you can search another medication for hypertension here.

Indications

Evipress is indicated for the treatment of mild to moderate essential hypertension.

Dosage and administration

The recommended dose is 1 tablet of 10 mg per day 15 minutes before meals. The dose may be increased to 20 mg depending on the individual response. The dose increase must be gradual since two weeks must pass to see the maximum antihypertensive effect. In the elderly, no dose adjustment is required. There is no experience in children.

Contraindications

Do not use Evipress if you have any of the following conditions/diseases:

  • hypersensitivity to dihydropyridines or the components of the formula;
  • pregnancy, lactation;
  • obstruction of the left ventricular outflow tract;
  • untreated congestive heart failure;
  • unstable angina pectoris;
  • severe renal or hepatic insufficiency;
  • during the first month after a heart attack myocardium.

Side effects

In rare cases, the medicine can cause blushing, peripheral edema, palpitations, tachycardia, headache, dizziness and asthenia. Fatigue, dyspepsia, nausea, vomiting, epigastralgia, diarrhea, polyuria, rash, drowsiness, myalgia, hypotension and gingival hyperplasia have also been reported.

Overdose

No cases reported. However, cardiovascular support is recommended by administering atropine IV for bradycardia and 24-hour surveillance.

See also  Valvulan (Digoxin)

Interaction

Caution is advised with medications that are metabolized in cytochrome P-450 3A4 (ketoconazole, itraconazole, erythromycin, carbamazepine, terfenadine, astemizole, cyclosporine, beta-blockers, etc.), as bioavailability and the hypotensive effect of lercanidipine can be increased. Patients treated with digoxin should be observed to control the signs of toxicity. Administration with anticonvulsants may reduce the antihypertensive effect of lercanidipine. Alcohol and grapefruit juice can enhance the hypotensive effect of lercanidipine.